Purolite™ Praesto™ 70 CH1

Addressing Impurity Challenges in Bispecific Purification

Antibody variants used in the development of therapeutic medicines have expanded, bringing innovative therapies to patients. However, traditional purification procedures have proven inefficient.

Purolite 70 CH1 is engineered to purify specialized mAbs, including bispecifics and antibody fragments, supporting the diversification of therapeutic molecules and clinical pipelines.

Offering up to twice the dynamic binding capacity of established CH1 resins, improving process economics in complex purification procedures.

Compared to established CH1 resins, Purolite 70 CH1 offers improved alkaline stability, allowing for the adoption of standard CIP protocols.
 

Purolite™ Chromatography Resins

Purolite 70 CH1 is manufactured using patented Jetting technology, ensuring uniform particle size for enhanced quality and performance. Jetting manufacturing supports sustainability through reduced use of harmful solvents and water usage.

Compared to traditional methods, Jetting accelerates time to market with fewer production steps.